{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:41:51Z","timestamp":1791513711094,"version":"4.3.4"},"reference-count":28,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2016,4,24]],"date-time":"2016-04-24T00:00:00Z","timestamp":1461456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2016,4,24]],"date-time":"2016-04-24T00:00:00Z","timestamp":1461456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Fuji Yakuhin Co., Ltd."},{"name":"Sanwa Kagaku Kenkyusho Co., Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1111\/jcpt.12391","type":"journal-article","created":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T04:52:41Z","timestamp":1461559961000},"page":"290-297","source":"Crossref","is-referenced-by-count":55,"title":["Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double\u2010blind, double\u2010dummy, active\u2010controlled, parallel\u2010group study"],"prefix":"10.1155","volume":"41","author":[{"given":"T.","family":"Hosoya","sequence":"first","affiliation":[{"name":"Department of Pathophysiology and Therapy in Chronic Kidney Disease Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Drug Development Center Sanwa Kagaku Kenkyusho Co. Ltd. Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Drug Development Center Sanwa Kagaku Kenkyusho Co. Ltd. Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Medical R&D Division Fuji Yakuhin Co. Ltd. Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Drug Development Center Sanwa Kagaku Kenkyusho Co. Ltd. Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2016,4,24]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"971","article-title":"Health\u2010related quality of life and treatment satisfaction in patients with gout: results from a cross\u2010sectional study in a managed care setting","volume":"9","author":"Khanna PP","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_7_3_1","first-page":"109","article-title":"Digest of guideline for the management of hyperuricemia and gout 2nd edition","volume":"34","author":"The Guideline Revising Committee of Japanese Society of Gout and Nucleic Acid Metabolism","year":"2010","journal-title":"Gout Nucleic Acid Metabolism"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30520"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.5387\/fms.2014-31"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.36.6.1072"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2011.01513.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000341490"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-12-31"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000355639"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2014.75"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.10.006"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01580210"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.08.091"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.174540"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/26.6.445"},{"key":"e_1_2_7_17_1","first-page":"639","article-title":"Pharmacokinetics and pharmacodynamics study of topiroxostat by oral administration in subjects with renal impairment","volume":"43","author":"Nakazawa T","year":"2015","journal-title":"Jpn Pharmacol Ther"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200501000-00005"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.011692"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.09.033"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-014-0935-8"},{"key":"e_1_2_7_22_1","first-page":"20","volume-title":"Guideline for the management of hyperuricemia and gout 1st edition: The classification of hyperuricemia (in Japanese)","author":"The Guideline Committee of Japanese Society of Gout, Nucleic Acid Metabolism","year":"2002"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2011.08.005"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2005.00670.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-5381-6_3"},{"key":"e_1_2_7_26_1","first-page":"69","article-title":"An Allopurinol\u2010controlled, double\u2010blind, comparative study of febuxostat (TMX\u201067), a new xanthine oxidoreductase inhibitor, in patients with hyperuricemia including those with gout (Phase III trial)","volume":"29","author":"Kamatani N","year":"2005","journal-title":"Gout Nucleic Acid Metabolism"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2001.01397-3.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31821d36cc"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12391","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jcpt.12391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jcpt.12391","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jcpt.12391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:01:24Z","timestamp":1671818484000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,24]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/jcpt.12391"],"URL":"https:\/\/doi.org\/10.1111\/jcpt.12391","archive":["Portico"],"relation":{},"ISSN":["0269-4727","1365-2710"],"issn-type":[{"value":"0269-4727","type":"print"},{"value":"1365-2710","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,24]]}}}